Spondyloarthritis

Madelaine A. Feldman, MD, FACR, shares about the current standard treatment rheumatoid arthritis and the hurdles to providing optimal treatment.

New data supports the use of etanercept as a monotherapy, or in combination, for the treatment of psoriatic arthritis.

Data from 2 phase 3 studies of secukinumab (Cosentyx) in patients with psoriatic arthritis and ankylosing spondylitis will be presented at an upcoming meeting.

New data from the FUTURE 5 study show that the interleukin-17A antagonist slows the progression of joint structural damage compared to placebo.

The trial is the first head-to-head clinical comparison in ankylosing spondylitis investigating the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.

The approval extends the rheumatoid arthritis treatment's label.

PsA is the second approved indication for Taltz in the US.

FDA to consider Xeljanz, the sole JAK inhibitor available in US, for new indication.

Infliximab-abda approved for range of gastroenterological and rheumatoid conditions.

Pso and PsA are associated with higher rates of pathological fractures.

Arthro-haptic 3D printed prototypes give patients an emotional experience.

People with Crohn's disease can also suffer from severe joint pain.

Canadian authorities today approved Sanofi/Regeneron collaboration sarilumab.

Understanding the cytokine’s role may be valuable in diagnosis and treatment.

It's well known that arthritis doesn't mix well with other conditions. But where does healthcare go with that information?

Dutch researchers used radiolabeling to observe certolizumab in the body for the first time. Such studies could provide a greater understanding of how TNF inhibitors can be best used in the treatment of inflammatory conditions like arthritis.

Researchers from the University of North Carolina examined the gene expression and regulation in colon tissue from patients to better understand the cellular and molecular mechanisms that make up Crohn’s disease.

With extensive literature review and expert input, the ACR and the American Association of Hip and Knee Surgeons (AAHKS) have come together to propose a set of guidelines for medication during the perioperative period for patients undergoing knee or hip arthroplasty.

Prescribing rheumatologists discussed drug interactions, costs, contraindications, and severity of side effects with less than 50% of the patients in the study to whom they had prescribed disease-modifying antirheumatic drugs.

Speaking at ACR 2016, the current chair of the Spondyloarthritis Research and Treatment Network (SPARTAN) presented data that showed that a combination of inflammatory drugs may inhibit ankylosis, the painful fusion of bones.

A new study out of Ireland examined the prevalence of extra-articular manifestations in axial spondyloarthritis, and found that women were at significantly higher risk for inflammatory bowel disease and uveitis than men.

A report out of Cedars-Sinai Medical Center shows a reduction in hip disease progression in ankylosing spondylitis patients who receive anti-tumor necrotics factor treatment.